Antisense Therapeutics Price To Book vs. Operating Margin

ATHJF Stock  USD 0.04  0.00  0.00%   
Based on Antisense Therapeutics' profitability indicators, Antisense Therapeutics Limited may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Antisense Therapeutics' ability to earn profits and add value for shareholders.
For Antisense Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Antisense Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Antisense Therapeutics Limited utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Antisense Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Antisense Therapeutics Limited over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Antisense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Antisense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Antisense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Antisense Therapeutics Operating Margin vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Antisense Therapeutics's current stock value. Our valuation model uses many indicators to compare Antisense Therapeutics value to that of its competitors to determine the firm's financial worth.
Antisense Therapeutics Limited is number one stock in price to book category among its peers. It also is number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Antisense Therapeutics' earnings, one of the primary drivers of an investment's value.

Antisense Operating Margin vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Antisense Therapeutics

P/B

 = 

MV Per Share

BV Per Share

 = 
3.05 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Antisense Therapeutics

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
(3.28) %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.

Antisense Operating Margin Comparison

Antisense Therapeutics is currently under evaluation in operating margin category among its peers.

Antisense Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Antisense Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Antisense Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Antisense Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Antisense Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Antisense Therapeutics Limited was incorporated in 2000 and is based in Toorak, Australia. Antisense Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.

Antisense Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Antisense Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Antisense Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Antisense Therapeutics' important profitability drivers and their relationship over time.

Use Antisense Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Antisense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Antisense Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Antisense Therapeutics Pair Trading

Antisense Therapeutics Limited Pair Trading Analysis

The ability to find closely correlated positions to Antisense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Antisense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Antisense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Antisense Therapeutics Limited to buy it.
The correlation of Antisense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Antisense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Antisense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Antisense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Antisense Therapeutics position

In addition to having Antisense Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Healthcare Thematic Idea Now

Healthcare
Healthcare Theme
Companies that provide healthcare goods and services including hospitals, health maintenance organizations, HMOs, or medical aid manufacturers. The Healthcare theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Antisense Pink Sheet

To fully project Antisense Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Antisense Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Antisense Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Antisense Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Antisense Therapeutics investors may work on each financial statement separately, they are all related. The changes in Antisense Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Antisense Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.